NanoZymeX
Developing a lipid nanoparticle platform for enhanced enzyme replacement therapy.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
NanoZymeX is a biotech startup spun out of research at the University of Basel. The company is developing a novel platform utilizing lipid nanoparticles to improve enzyme replacement therapies for rare genetic conditions, such as Pompe disease. Their technology aims to enhance the delivery of therapeutic enzymes into target cells and lysosomes, thereby increasing therapeutic activity in affected tissues and reducing immune responses to repeated treatments.
Similar companies
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Therapeutics
Developing disease-responsive advanced therapies through programmable gene control technology.
Shares Biotechnology, Drug Delivery
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Therapeutics
Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
Shares Biotechnology, Therapeutics
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Shares Biotechnology, Therapeutics
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Therapeutics
Key facts
- Headquarters
- Basel, Switzerland
- Total funding
- $160K (Pre-Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 24 Mar 2026 | Pre-Seed | $160K | Venture Kick |
Frequently asked
What does NanoZymeX do?
The platform is designed to improve existing enzyme therapies and can be adapted to multiple lysosomal storage disorders. NanoZymeX plans to partner with pharmaceutical and biotechnology companies to bring next-generation enzyme therapies to patients.
How much funding has NanoZymeX raised?
NanoZymeX has raised a total of $160K in funding. The most recent round on record is Pre-Seed.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for NanoZymeX
